Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its holdings in Xencor, Inc. (NASDAQ:XNCR) by 17.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,103,758 shares of the biopharmaceutical company’s stock after selling 1,520,616 shares during the period. Vanguard Group Inc. owned 9.96% of Xencor worth $83,327,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its stake in shares of Xencor by 4.8% in the 3rd quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 947 shares during the last quarter. HighVista Strategies LLC increased its position in shares of Xencor by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 1,362 shares during the last quarter. GAMMA Investing LLC raised its holdings in Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,449 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Xencor by 9.1% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,525 shares during the last quarter. Finally, State of Tennessee Department of Treasury lifted its position in Xencor by 6.2% in the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 1,784 shares during the last quarter.

More Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an EPS beat for the latest quarter and retains a strong liquidity position (high current/quick ratios), which cushions near?term financing risk and supports ongoing R&D programs. MarketBeat: Xencor company page
• Neutral Sentiment: CEO Bassil Dahiyat disclosed a sale of 6,758 shares at about $11.90 (roughly $80k). The sale reduced his stake by ~1.18% and may reflect routine diversification rather than a company-specific signal. SEC Form 4: CEO sale
• Negative Sentiment: Reported royalty rift: Alexion has cut off U.S. royalty payments to Xencor tied to Ultomiris, and Xencor said it is revising its Ultomiris royalty revenue forecast — a direct hit to near?term revenue and the main catalyst for the share decline. Benzinga: Royalty rift report Company announcement: royalty forecast change
• Negative Sentiment: Additional insider sales: SVP Celia Eckert and VP John Desjarlais sold shares the same day (small percent reductions of their holdings). The cluster of insider sales has heightened investor concern about insider timing and added to negative sentiment. InsiderTrades: insider sale report

Analysts Set New Price Targets

A number of research analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Truist Financial began coverage on Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 target price on the stock. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Finally, Barclays increased their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Insider Buying and Selling

In related news, VP John R. Desjarlais sold 2,663 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $31,689.70. Following the transaction, the vice president owned 270,451 shares of the company’s stock, valued at $3,218,366.90. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Bassil I. Dahiyat sold 6,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total value of $80,420.20. Following the completion of the sale, the chief executive officer owned 567,792 shares in the company, valued at approximately $6,756,724.80. This represents a 1.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 198,657 shares of company stock worth $3,080,057. Insiders own 4.76% of the company’s stock.

Xencor Price Performance

XNCR stock opened at $11.16 on Friday. The business’s 50-day moving average is $12.87 and its two-hundred day moving average is $12.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. The firm has a market capitalization of $818.47 million, a P/E ratio of -9.00 and a beta of 0.95. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The firm had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.62) earnings per share. Analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.